Related Experiment Video
Updated: Apr 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial)
Apurva O Badheka1, Nileshkumar J Patel2, Peeyush M Grover3
1Detroit Medical Center, Detroit, Michigan.
Insights
In patients with atrial fibrillation (AF), blood pressure (BP) shows a U-shaped relationship with mortality. Optimal BP may be higher than in the general population, with risks increasing below 110/60 mm Hg.
Area of Science:
- Cardiology
- Clinical Research
Background:
- Many atrial fibrillation (AF) medications lower blood pressure (BP).
- The relationship between BP and mortality in AF patients is not well understood.
Purpose of the Study:
- To investigate the association between blood pressure and mortality in patients with atrial fibrillation.
Main Methods:
- Post hoc analysis of 3,947 participants from the AFFIRM trial.
- Systolic (SBP) and diastolic (DBP) blood pressures categorized in 10-mm Hg increments.
- Multivariate analysis and nonlinear Cox proportional hazards model used.
Main Results:
- A U-shaped relationship was observed between SBP/DBP and all-cause mortality (ACM) and secondary outcomes.
- The lowest ACM incidence occurred at a BP of 140/78 mm Hg.
- Increased ACM was noted with BP <110/60 mm Hg (HR 2.4 for SBP and DBP).
Conclusions:
- A U-shaped relationship exists between BP and ACM in AF patients.
- Optimal BP targets for AF patients may differ from the general population.
- Aggressive BP reduction (<110/60 mm Hg) with AF pharmacologic therapy may increase mortality risk.
Abstract:
Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.
Related Concept Videos
Atherosclerosis III: Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Errors occurring during blood pressure monitoring
Several factors...
Hypertension V: Nursing Management
Heart Failure V: Medical Management
Pre-Procedural Guidelines for Assessing Blood Pressure

